GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gopro Inc. (GPRO) [hlAlert]

Rating:
Buy GPRO
up 13.33 %

Gen-probe Incorporated (GPRO) rated Buy with price target $54 by Maxim Group

Posted on: Thursday,  Jul 30, 2009  8:25 AM ET by Maxim Group

Maxim Group rated Buy Gopro Inc. (NASDAQ: GPRO) on 07/30/2009, when the stock price was $42.14. Since
then, Gopro Inc. has gained 13.34% as of 01/14/2016's recent price of $47.76.
If you would have followed this Maxim Group's recommendation on GPRO, you would have gained 13.33% of your investment in 2359 days.

Gen-Probe Inc. is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/30/2009 8:25 AM Buy
None
42.14 54.00
as of 12/31/2009
1 Week up  40.73 %
1 Month up  47.25 %
3 Months up  48.14 %
1 YTD up  45.68 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy